Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3616MR)

This product GTTS-WQ3616MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3616MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5723MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ11021MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ11408MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ7794MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ618MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10406MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ12389MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ14266MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7116
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW